Generic Medicine Info
Hypersensitivity. Pregnancy and lactation.
Special Precautions
Patient with bone marrow suppression (e.g. thrombocytopenia, leucopenia), reduced lung function or pre-existing lung disease. Children. Monitoring Parameters Monitor CBC with differential and platelet count weekly for at least 6 weeks after a dose; pulmonary, renal, and hepatic function periodically. Implant: Monitor for seizures, impaired neurosurgical wound healing; signs and symptoms of meningitis, CNS infection, and obstruction hydrocephalus.
Adverse Reactions
Significant: Bone marrow suppression (e.g. thrombocytopenia, leucopenia), hepatotoxicity (reversible increased serum transaminase, alkaline phosphatase and bilirubin), renal failure, progressive azotemia; intracranial hypertension, wound healing impairment (implant); secondary malignancies (long-term IV use). Cardiac disorders: Hypotension, tachycardia, chest pain. Eye disorders: Conjunctival flushing, blurred vision, retinal haemorrhage. Gastrointestinal disorders: Nausea, vomiting, anorexia, constipation, diarrhea, stomatitis. Nervous system disorders: Dizziness, somnolence, hemiplegia, convulsion, brain oedema. Psychiatric disorders: Depression, anxiety, abnormal thinking, hallucinations. Reproductive system and breast disorders: Gynecomastia. Respiratory, thoracic and mediastinal disorders: Pulmonary embolism. Skin and subcutaneous tissue disorders: Hyperpigmentation (in skin exposure), rash, alopecia. Vascular disorders: Phlebitis.
Potentially Fatal: Pulmonary fibrosis, opportunistic infections.
Drug Interactions
May enhance myelosuppressive effects with cimetidine. Increased risk of pulmonary toxicity with melphalan. Decreased antiepileptic activity of phenytoin. Decreased absorption of digoxin.
CIMS Class
Cytotoxic Chemotherapy
ATC Classification
L01AD01 - carmustine ; Belongs to the class of alkylating agents, nitrosoureas. Used in the treatment of cancer.
Disclaimer: This information is independently developed by CIMS based on carmustine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in